Plasma levels of soluble VEGF receptor isoforms, circulating pterins and VEGF system SNPs as prognostic biomarkers in patients with acute coronary syndromes

Table 4 Cox’s proportional hazards regression model for mortality in the subgroup of the CDCS cohort assayed for sFlt-1 (n = 476, 143 deaths)

	Coefficient	SE	Wald	df	Significance	Hazard Ratio	95% CI for HR
	Coefficient	SE	Wald	df	Significance	Hazard Ratio	Lower	Upper
Age at baseline	0.07	0.01	35.1	1	< 0.001	1.07	1.05	1.10
Male Gender	0.14	0.22	0.004	1	0.951	1.01	0.66	1.56
Log₁₀ NTpro-BNP at baseline^a	0.90	0.29	9.71	1	0.002	2.46	1.40	4.33
Log₁₀ sFlt-1 at baseline^a	1.10	0.49	5.15	1	0.023	3.00	1.16	7.76
Creatinine baseline	0.01	0.001	16.8	1	< 0.001	1.01	1.00	1.01
Log₁₀Troponin I at baseline^a	0.02	0.19	0.02	1	0.900	1.02	0.70	1.50
Physical Activity (scale 1–4)^b	−0.32	0.07	18.5	1	< 0.001	0.73	0.63	0.84
Alcohol consumption category^c			3.25	2	0.197
Non-drinker v Current Drinker	−0.21	0.12	2.99	1	0.84	0.81	0.63	1.03
Non-drinker v Ex-drinker	0.08	0.17	0.25	1	0.62	1.09	0.79	1.50
Previous Myocardial Infarction	0.49	0.20	6.17	1	0.013	1.62	1.11	2.38
Type 2 Diabetes	0.32	0.22	2.08	1	0.149	1.38	0.89	2.14
Ethnicity			1.05	3	0.789
European v Maori/Pasifika	0.24	0.60	0.16	1	0.691	1.27	0.39	2.11
European v Other	0.98	1.05	0.88	1	0.349	2.67	0.34	20.8
European v Unknown	11.5	201	0.003	1	0.954	< 0.01	< 0.01	2.9 × 10¹⁶⁶
Acute Coronary Syndrome Diagnosis			1.31	2	0.518
NSTEMI v STEMI	−0.20	0.28	0.48	1	0.488	0.82	0.47	1.43
NSTEMI v Unstable Angina	−0.21	0.21	1.01	1	0.315	0.81	0.54	1.22
Time to Sampling^d	−0.001	0.01	0.02	1	0.901	0.99	0.98	1.02

^aHazard Ratio represents the change in risk for every 10-fold increase in analyte level
^bScore of 1 = sedentary, 2 = < 30 min activity on > 2 days/week, 3=≥30 min on 2 days/week, 4= ≥30 min on ≥3 days/week
^cCurrent Drinker, Ex-drinker or Non-drinker
^dDays between index admission and plasma sampling at recruitment visit

ISSN: 1471-2261